VR Logo

Phathom Pharmaceuticals Inc. (PHAT) download report


Healthcare | Biotechnology & Pharma Research

Phathom Pharmaceuticals Inc. (PHAT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

IPO Date: 25-Oct-2019

Pres, CEO & Director: Ms. Terrie J. Curran

Co-Founder & Director: Mr. David A. Socks

Listing: NASDAQ: PHAT

Country: United States

Headquarters: Florham Park, NJ

Website: https://www.phathompharma.com

Key Facts

Market cap: $354.38 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-149.71 Mln

Cash: $138.09 Mln

Total Debt: $92.61 Mln

Insider's Holding: 24.48%

Liquidity: Low

52 Week range: $6.10 - 37.17

Shares outstanding: 39,072,000

Stock Performance

Time Period Phathom Pharmaceuticals (PHAT) S&P BSE Sensex* S&P Small-Cap 600*
YTD-53.89-8.62-18.78
1 month21.91-4.54-8.00
3 months-33.36-10.19-13.65
1 Year-73.211.43-17.19
3 Years--10.146.10
5 Years--11.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Phathom Pharmaceuticals (PHAT) S&P Small-Cap 600 S&P BSE Sensex
2021-40.7925.2721.99
20206.689.5715.75